Review



mouse cfd  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    R&D Systems mouse cfd
    <t>Adipocyte</t> <t>ESRRA</t> positively regulates <t>Cfd</t> transcriptional expression responding to bone marrow adipocytes expansion. a Venn diagram of overlapping differentially expressed genes from RNA-seq of HFHC-fed gWAT and BMAds lineage cells in Esrra fl/fl and Esrra AKO mice ( GSE248799 ), identifying six downregulated genes encoding secreted factors. b Heatmap of selected genes. c Cf d mRNA in HFHC-fed gWAT ( n = 6) and fully differentiated mBMAds ( n = 5). d Schematic of ERRE binding sites on the mouse Cfd promoter, with ChIP fragments indicated as region 1 and 2 (R1, R2). e Luciferase activity of Cfd promoter in 3T3‑L1 cells transfected with Esrra or Ppargc1a expression plasmids ( n = 5). f Effects of compound 29 (C29) or andrographolide (AP) on ESRRA/PPARGC1A- driven Cfd promoter activity ( n = 5). g Luciferase activities of the R2-deleted (ΔR2-luc), S2-mutated (MutS2-luc) and wild-type (WT-luc) Cfd promoter ( n = 5). h ChIP assays with ESRRA antibody or IgG control in BMSCs after 4 days of adipogenic induction, with cells infected with ESRRA- or GFP-expressing adenovirus ( n = 4). i Enrichment of ESRRA at Cfd promoter in BMSCs undergoing adipogenic induction from Esrra fl/fl and Esrra AKO mice ( n = 4). j , k Immunoblots of serum CFD from HFHC-fed ( j ) and aged ( k ) groups versus control diet (CD). Ponceau S as loading control (L.C). l Serum CFD levels ( n = 6). m , n Immunoblots of CFD and Leptin in gWAT from Esrra fl/fl and Esrra AKO mice as in ( j , k ). o CFD concentrations from culture medium of gWAT explants as in ( j , k ) ( n = 5). p , q Immunoblots of bone marrow CFD as in ( j , k ). r Protein levels of ESRRA, CFD and Leptin in BMSCs and mBMAds with treatment of dexamethasone (DEX) with or without rosiglitazone (Rosi). Data are shown as mean ± SD. Statistical analysis is performed using two-sided unpaired Student’s t -test ( c ), two-way ANOVA with post-hoc Turkey’s multiple comparisons test ( l , o )
    Mouse Cfd, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 15 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/complement+factor+antibodies/Mouse+Complement+Factor+D%2FAdipsin+Antibody/pmc13128952-365-19-22
    Average 93 stars, based on 15 article reviews
    mouse cfd - by Bioz Stars, 2026-11
    93/100 stars

    Images

    1) Product Images from "Targeting adipocyte ESRRA alleviates osteoarthritis via interrupting inter-organelle crosstalk of complement C3-CFD-MAC cascade"

    Article Title: Targeting adipocyte ESRRA alleviates osteoarthritis via interrupting inter-organelle crosstalk of complement C3-CFD-MAC cascade

    Journal: Bone Research

    doi: 10.1038/s41413-026-00527-3

    Adipocyte ESRRA positively regulates Cfd transcriptional expression responding to bone marrow adipocytes expansion. a Venn diagram of overlapping differentially expressed genes from RNA-seq of HFHC-fed gWAT and BMAds lineage cells in Esrra fl/fl and Esrra AKO mice ( GSE248799 ), identifying six downregulated genes encoding secreted factors. b Heatmap of selected genes. c Cf d mRNA in HFHC-fed gWAT ( n = 6) and fully differentiated mBMAds ( n = 5). d Schematic of ERRE binding sites on the mouse Cfd promoter, with ChIP fragments indicated as region 1 and 2 (R1, R2). e Luciferase activity of Cfd promoter in 3T3‑L1 cells transfected with Esrra or Ppargc1a expression plasmids ( n = 5). f Effects of compound 29 (C29) or andrographolide (AP) on ESRRA/PPARGC1A- driven Cfd promoter activity ( n = 5). g Luciferase activities of the R2-deleted (ΔR2-luc), S2-mutated (MutS2-luc) and wild-type (WT-luc) Cfd promoter ( n = 5). h ChIP assays with ESRRA antibody or IgG control in BMSCs after 4 days of adipogenic induction, with cells infected with ESRRA- or GFP-expressing adenovirus ( n = 4). i Enrichment of ESRRA at Cfd promoter in BMSCs undergoing adipogenic induction from Esrra fl/fl and Esrra AKO mice ( n = 4). j , k Immunoblots of serum CFD from HFHC-fed ( j ) and aged ( k ) groups versus control diet (CD). Ponceau S as loading control (L.C). l Serum CFD levels ( n = 6). m , n Immunoblots of CFD and Leptin in gWAT from Esrra fl/fl and Esrra AKO mice as in ( j , k ). o CFD concentrations from culture medium of gWAT explants as in ( j , k ) ( n = 5). p , q Immunoblots of bone marrow CFD as in ( j , k ). r Protein levels of ESRRA, CFD and Leptin in BMSCs and mBMAds with treatment of dexamethasone (DEX) with or without rosiglitazone (Rosi). Data are shown as mean ± SD. Statistical analysis is performed using two-sided unpaired Student’s t -test ( c ), two-way ANOVA with post-hoc Turkey’s multiple comparisons test ( l , o )
    Figure Legend Snippet: Adipocyte ESRRA positively regulates Cfd transcriptional expression responding to bone marrow adipocytes expansion. a Venn diagram of overlapping differentially expressed genes from RNA-seq of HFHC-fed gWAT and BMAds lineage cells in Esrra fl/fl and Esrra AKO mice ( GSE248799 ), identifying six downregulated genes encoding secreted factors. b Heatmap of selected genes. c Cf d mRNA in HFHC-fed gWAT ( n = 6) and fully differentiated mBMAds ( n = 5). d Schematic of ERRE binding sites on the mouse Cfd promoter, with ChIP fragments indicated as region 1 and 2 (R1, R2). e Luciferase activity of Cfd promoter in 3T3‑L1 cells transfected with Esrra or Ppargc1a expression plasmids ( n = 5). f Effects of compound 29 (C29) or andrographolide (AP) on ESRRA/PPARGC1A- driven Cfd promoter activity ( n = 5). g Luciferase activities of the R2-deleted (ΔR2-luc), S2-mutated (MutS2-luc) and wild-type (WT-luc) Cfd promoter ( n = 5). h ChIP assays with ESRRA antibody or IgG control in BMSCs after 4 days of adipogenic induction, with cells infected with ESRRA- or GFP-expressing adenovirus ( n = 4). i Enrichment of ESRRA at Cfd promoter in BMSCs undergoing adipogenic induction from Esrra fl/fl and Esrra AKO mice ( n = 4). j , k Immunoblots of serum CFD from HFHC-fed ( j ) and aged ( k ) groups versus control diet (CD). Ponceau S as loading control (L.C). l Serum CFD levels ( n = 6). m , n Immunoblots of CFD and Leptin in gWAT from Esrra fl/fl and Esrra AKO mice as in ( j , k ). o CFD concentrations from culture medium of gWAT explants as in ( j , k ) ( n = 5). p , q Immunoblots of bone marrow CFD as in ( j , k ). r Protein levels of ESRRA, CFD and Leptin in BMSCs and mBMAds with treatment of dexamethasone (DEX) with or without rosiglitazone (Rosi). Data are shown as mean ± SD. Statistical analysis is performed using two-sided unpaired Student’s t -test ( c ), two-way ANOVA with post-hoc Turkey’s multiple comparisons test ( l , o )

    Techniques Used: Expressing, RNA Sequencing, Binding Assay, Luciferase, Activity Assay, Transfection, Control, Infection, Western Blot

    Reduced CFD from Esrra -ablated BMAds interrupts C3-CFD-MAC cascade-mediated mitochondrial dysfunction, senescence and catabolism in chondrocytes. a , b Representative images ( a ) and quantification ( b ) of MAC and pERK1/2 positive staining in cartilage regions of HFHC-fed or 25-month-old Esrra fl/fl and Esrra AKO mice. Scale bar, 100 μm. n = 6 mice. c Diagram depicting primary wild-type chondrocytes treated with the indicated conditioned medium (CM) collected from mBMAds, with or without supplementation of 1 μg/mL mouse recombinant C3 (mC3). d Soluble CFD concentrations from BMAds CM prepared as in ( c ) ( n = 6). e mRNA levels of degradative enzymes Mmp13 , Mmp3 , Mmp9 , Adamts4 , Adamts5 and senescent/proinflammatory markers P16 , P53 , P21 , IL6 in co-cultured primary chondrocytes as in ( c ) ( n = 5). f Protein levels of pERK1/2, ERK1/2, P21, MMP13 and COL2A1 in co-cultured primary chondrocytes as in ( c ). g , h Immunofluorescence staining of MAC, pERK1/2, MitoTracker Red, MitoSOX Red, γH2AX, P21 and Ki67, as well as SA-β-gal staining in co-cultured primary chondrocytes ( g ). Quantitative analysis results are shown in ( h ) ( n = 4). DAPI or Hoechst was used for nuclear counterstaining. Scale bar, 10 μm. i Oxygen Consumption Rate (OCR) were measured in co-cultured primary chondrocytes as in ( c ). Bar chart showing the results of mitochondrial basal and maximal respiratory capacity changes ( n = 9). Data are shown as mean ± SD. Statistical analysis is performed using two-sided unpaired Student’s t -test ( b , d ), two-way ANOVA with post-hoc Turkey’s multiple comparisons test ( e , h , i )
    Figure Legend Snippet: Reduced CFD from Esrra -ablated BMAds interrupts C3-CFD-MAC cascade-mediated mitochondrial dysfunction, senescence and catabolism in chondrocytes. a , b Representative images ( a ) and quantification ( b ) of MAC and pERK1/2 positive staining in cartilage regions of HFHC-fed or 25-month-old Esrra fl/fl and Esrra AKO mice. Scale bar, 100 μm. n = 6 mice. c Diagram depicting primary wild-type chondrocytes treated with the indicated conditioned medium (CM) collected from mBMAds, with or without supplementation of 1 μg/mL mouse recombinant C3 (mC3). d Soluble CFD concentrations from BMAds CM prepared as in ( c ) ( n = 6). e mRNA levels of degradative enzymes Mmp13 , Mmp3 , Mmp9 , Adamts4 , Adamts5 and senescent/proinflammatory markers P16 , P53 , P21 , IL6 in co-cultured primary chondrocytes as in ( c ) ( n = 5). f Protein levels of pERK1/2, ERK1/2, P21, MMP13 and COL2A1 in co-cultured primary chondrocytes as in ( c ). g , h Immunofluorescence staining of MAC, pERK1/2, MitoTracker Red, MitoSOX Red, γH2AX, P21 and Ki67, as well as SA-β-gal staining in co-cultured primary chondrocytes ( g ). Quantitative analysis results are shown in ( h ) ( n = 4). DAPI or Hoechst was used for nuclear counterstaining. Scale bar, 10 μm. i Oxygen Consumption Rate (OCR) were measured in co-cultured primary chondrocytes as in ( c ). Bar chart showing the results of mitochondrial basal and maximal respiratory capacity changes ( n = 9). Data are shown as mean ± SD. Statistical analysis is performed using two-sided unpaired Student’s t -test ( b , d ), two-way ANOVA with post-hoc Turkey’s multiple comparisons test ( e , h , i )

    Techniques Used: Staining, Recombinant, Cell Culture, Immunofluorescence

    Inhibition of adipocyte ESRRA/CFD signaling rescues chondrocyte from damage caused by excessive hepatocytes-derived C3 under metabolic stress conditions. a Boxplots depicting C3 gene expression levels in MASLD/MASH patients compared to healthy controls from European ( GSE135251 ) and American ( GSE24807 ) cohorts. Data are represented as box and whiskers with bars representing maximum and minimum values and with median highlighted as a line. b Immunoblot analysis of C3 expression in livers from female mice at various time points following OVX (left) and male mice across different ages (right). c Representative liver images of the livers from HFHC-fed or 25-month-old Esrra fl/fl and Esrra AKO mice as well as corresponding controls. d Protein levels of C3 in the livers as in ( c ). e ELISA analysis of serum C3 concentrations. n = 6 mice per group. f The expression and secretion of C3 protein in primary hepatocytes following treatment with 40 μmol/L cholesterol (Chol) or a mixture of 250 μmol/L oleic acid (OA)/125 μmol/L palmitic acid (PA) for 24 hours (n = 4). g Diagram illustrating the co-culture system involving mBMAds CM, mouse primary hepatocytes and chondrocytes. h Western blot analysis of pERK1/2, ERK1/2, P21, MMP13 and COL2A1 in co-cultured primary chondrocytes as in ( g ). i , j Representative images ( i ) and quantitative analysis ( j ) of MAC, pERK1/2, MitoTracker Red, MitoSOX Red, γH2AX, P21, Ki67 and SA-β-gal staining in chondrocytes as in ( g ) ( n = 4). DAPI or Hoechst was used for counterstaining of nuclei. Scale bar, 10 μm. Data are shown as mean ± SD. Statistical analysis is performed using two-sided unpaired Student’s t -test (right panel of a ), two-way ANOVA with post-hoc Turkey’s multiple comparisons test ( e , j ), one-way ANOVA followed by Bonferroni’s post hoc tests (left panel of a , f )
    Figure Legend Snippet: Inhibition of adipocyte ESRRA/CFD signaling rescues chondrocyte from damage caused by excessive hepatocytes-derived C3 under metabolic stress conditions. a Boxplots depicting C3 gene expression levels in MASLD/MASH patients compared to healthy controls from European ( GSE135251 ) and American ( GSE24807 ) cohorts. Data are represented as box and whiskers with bars representing maximum and minimum values and with median highlighted as a line. b Immunoblot analysis of C3 expression in livers from female mice at various time points following OVX (left) and male mice across different ages (right). c Representative liver images of the livers from HFHC-fed or 25-month-old Esrra fl/fl and Esrra AKO mice as well as corresponding controls. d Protein levels of C3 in the livers as in ( c ). e ELISA analysis of serum C3 concentrations. n = 6 mice per group. f The expression and secretion of C3 protein in primary hepatocytes following treatment with 40 μmol/L cholesterol (Chol) or a mixture of 250 μmol/L oleic acid (OA)/125 μmol/L palmitic acid (PA) for 24 hours (n = 4). g Diagram illustrating the co-culture system involving mBMAds CM, mouse primary hepatocytes and chondrocytes. h Western blot analysis of pERK1/2, ERK1/2, P21, MMP13 and COL2A1 in co-cultured primary chondrocytes as in ( g ). i , j Representative images ( i ) and quantitative analysis ( j ) of MAC, pERK1/2, MitoTracker Red, MitoSOX Red, γH2AX, P21, Ki67 and SA-β-gal staining in chondrocytes as in ( g ) ( n = 4). DAPI or Hoechst was used for counterstaining of nuclei. Scale bar, 10 μm. Data are shown as mean ± SD. Statistical analysis is performed using two-sided unpaired Student’s t -test (right panel of a ), two-way ANOVA with post-hoc Turkey’s multiple comparisons test ( e , j ), one-way ANOVA followed by Bonferroni’s post hoc tests (left panel of a , f )

    Techniques Used: Inhibition, Derivative Assay, Gene Expression, Western Blot, Expressing, Enzyme-linked Immunosorbent Assay, Co-Culture Assay, Cell Culture, Staining

    Suppressing CFD by Danicopan or andrographolide confers protection against cellular senescence and catabolism in human C28/I2 chondrocytes. a Scatter plot showing plasma CFD levels across the lifespan were analyzed using a public proteome dataset (see Method for details). RFU, relative fluorescent unit. b Illustration of the co-culture system involving C28/I2 chondrocytes and conditioned medium (CM) obtained from AP-treated human BMAds (hBMAds), with an additional treatment of 1 μg/mL human recombinant C3 (hC3) and/or 10 mmol/L Danicopan. c Western blot analysis of ESRRA, CFD and Leptin protein levels in human BMSCs-derived BMAds treated with 40 μmol/L AP or DMSO for 2 days. d Western blot analysis of pERK1/2, ERK1/2, P21, MMP13, and COL2A1 protein levels in human C28/I2 chondrocytes as in ( b ). e , f Representative images ( e ) and corresponding quantitative data ( f ) of MAC, pERK1/2, MitoTracker Red, MitoSOX Red, γH2AX, P21, Ki67 and SA-β-gal staining in human C28/I2 chondrocytes as in ( b ) ( n = 4). DAPI or Hoechst was used for nuclear counterstaining. Scale bar, 10 μm. Data are shown as mean ± SD. Statistical analysis is performed using two-way ANOVA with post-hoc Turkey’s multiple comparisons test
    Figure Legend Snippet: Suppressing CFD by Danicopan or andrographolide confers protection against cellular senescence and catabolism in human C28/I2 chondrocytes. a Scatter plot showing plasma CFD levels across the lifespan were analyzed using a public proteome dataset (see Method for details). RFU, relative fluorescent unit. b Illustration of the co-culture system involving C28/I2 chondrocytes and conditioned medium (CM) obtained from AP-treated human BMAds (hBMAds), with an additional treatment of 1 μg/mL human recombinant C3 (hC3) and/or 10 mmol/L Danicopan. c Western blot analysis of ESRRA, CFD and Leptin protein levels in human BMSCs-derived BMAds treated with 40 μmol/L AP or DMSO for 2 days. d Western blot analysis of pERK1/2, ERK1/2, P21, MMP13, and COL2A1 protein levels in human C28/I2 chondrocytes as in ( b ). e , f Representative images ( e ) and corresponding quantitative data ( f ) of MAC, pERK1/2, MitoTracker Red, MitoSOX Red, γH2AX, P21, Ki67 and SA-β-gal staining in human C28/I2 chondrocytes as in ( b ) ( n = 4). DAPI or Hoechst was used for nuclear counterstaining. Scale bar, 10 μm. Data are shown as mean ± SD. Statistical analysis is performed using two-way ANOVA with post-hoc Turkey’s multiple comparisons test

    Techniques Used: Clinical Proteomics, Co-Culture Assay, Recombinant, Western Blot, Derivative Assay, Staining

    Pharmacological inhibition of ESRRA by andrographolide protects aged mice against spontaneous osteoarthritis progression. a Schematic diagram of the experimental design for pharmacological treatments in mice. 22-month-old male C57BL/6 mice were administered intragastrically (i.g.) with either vehicle or AP (100 mg/kg body weight) five times per week for 3 months. Young controls were 3-month-old male mice. b Representative images of WAT depots and livers, along with WAT weight analysis. c Liver TC and TG levels. d Immunoblots of C3 in liver tissues. e Serum C3 levels. f Immunoblots of bone marrow CFD and Leptin. g Serum CFD levels. h , i Immunofluorescence of PLIN1 staining ( h ) and quantification of PLIN1 + bone marrow adipocytes area ( i ). Scale bar, 100 μm. j Representative SO&FG-stained joint sections and H&E-stained synovial tissue. Scale bar, 100 μm. k , l OARSI score ( k ) and synovitis score ( l ). m Digital microCT images of knee joints. n , Quantitative data of the volume of calcified meniscus and synovial tissue. o , p Immunofluorescence staining for MAC and pERK1/2 in articular cartilage ( o ) and the quantitation ( p ). Scale bar, 100 μm. q – t Immunofluorescence staining ( q , r ) and quantification ( s , t ) of p21, Ki67, MMP13 and COL2A1. Scale bar, 100 μm. u A proposed model illustrates that ESRRA-mediated adipocyte CFD and liver-derived C3 synergistically promote osteoarthritis progression in aging and metabolic disorders. ESRRA transcriptionally upregulates CFD responding to MAT expansion. Together with steatotic liver-derived C3, this triggers excessive alternative complement activation, resulting in MAC deposition on chondrocytes, therefore provoking pERK1/2 activation and mitochondrial dysfunction. Targeting ESRRA alleviates osteoarthritis by interrupting this inter-organ C3-CFD-MAC cascade. For all experiments, n = 6 mice. Data are shown as mean ± SD. Statistical analysis is performed using two-way ANOVA with post-hoc Turkey’s multiple comparisons test
    Figure Legend Snippet: Pharmacological inhibition of ESRRA by andrographolide protects aged mice against spontaneous osteoarthritis progression. a Schematic diagram of the experimental design for pharmacological treatments in mice. 22-month-old male C57BL/6 mice were administered intragastrically (i.g.) with either vehicle or AP (100 mg/kg body weight) five times per week for 3 months. Young controls were 3-month-old male mice. b Representative images of WAT depots and livers, along with WAT weight analysis. c Liver TC and TG levels. d Immunoblots of C3 in liver tissues. e Serum C3 levels. f Immunoblots of bone marrow CFD and Leptin. g Serum CFD levels. h , i Immunofluorescence of PLIN1 staining ( h ) and quantification of PLIN1 + bone marrow adipocytes area ( i ). Scale bar, 100 μm. j Representative SO&FG-stained joint sections and H&E-stained synovial tissue. Scale bar, 100 μm. k , l OARSI score ( k ) and synovitis score ( l ). m Digital microCT images of knee joints. n , Quantitative data of the volume of calcified meniscus and synovial tissue. o , p Immunofluorescence staining for MAC and pERK1/2 in articular cartilage ( o ) and the quantitation ( p ). Scale bar, 100 μm. q – t Immunofluorescence staining ( q , r ) and quantification ( s , t ) of p21, Ki67, MMP13 and COL2A1. Scale bar, 100 μm. u A proposed model illustrates that ESRRA-mediated adipocyte CFD and liver-derived C3 synergistically promote osteoarthritis progression in aging and metabolic disorders. ESRRA transcriptionally upregulates CFD responding to MAT expansion. Together with steatotic liver-derived C3, this triggers excessive alternative complement activation, resulting in MAC deposition on chondrocytes, therefore provoking pERK1/2 activation and mitochondrial dysfunction. Targeting ESRRA alleviates osteoarthritis by interrupting this inter-organ C3-CFD-MAC cascade. For all experiments, n = 6 mice. Data are shown as mean ± SD. Statistical analysis is performed using two-way ANOVA with post-hoc Turkey’s multiple comparisons test

    Techniques Used: Inhibition, Western Blot, Immunofluorescence, Staining, Quantitation Assay, Derivative Assay, Activation Assay

    Related Articles

    Incubation:

    Article Title: Proteomic analysis reveals angiogenesis-related plasma proteins associated with pre-eclampsia in SLE.
    Article Snippet: .. 96- well half- area microplates (#3690, Corning) were coated with anti- CFHR5 antibody (#MAB3845, R&D Systems) diluted to 1.5 μg/mL in PBS and incubated overnight at RT. .. Plates were washed two times with 0.05% Tween in PBS and then blocked with 1% bovine serum albumin (BSA) (A4503, Sigma- Aldrich) in PBS for 1 hour at RT.

    Article Title: A novel fusion protein reduces kidney complement in experimental C3 glomerulopathy
    Article Snippet: .. After incubation and washing, bound FHR5 1-9 FH 1-5 was detected using goat polyclonal anti-CFHR5 antibody (R&D systems), followed by mouse anti-goat/sheep IgG-HRP (Sigma) and finally TMB substrate (BD). ..

    Article Title: Proteomic analysis reveals angiogenesis-related plasma proteins associated with pre-eclampsia in SLE.
    Article Snippet: After washing plates once with 0.05% tween in PBS, plasma samples and standard Recombinant Human FGF- 5 Protein (#3845- F5- 050, R&D Systems) were added and incubated for 2 hour at RT. .. After washing three times, anti- CFHR5 biotinylated antibody (#BAF3845, R&D Systems) (diluted to 0.1 μg/mL in 1% BSA in PBS) was added and incubated for 2 hour at RT. .. Again, plates were washed three times and then incubated with streptavidin- horseradish peroxidase (SA- HRP) (#DY998, R&D Systems) for 20 min at RT.

    Article Title: Sialoglycoconjugate Profiling of Human Choroid, Retinal Pigment Epithelium, and Macular Degeneration Related Lesions
    Article Snippet: After washes, sections were incubated with 25 μg/mL avidin-Texas red, 2.5 μg/mL donkey anti-rabbit IgG Alexa Fluor 647 (Invitrogen #A-31573, Waltham, MA), 2.5 μg/mL donkey anti-mouse IgG Alexa Fluor 488 (Invitrogen #A-21202, Waltham, MA), and 0.2 μg/mL DAPI for 45 minutes. .. For the second set, sections were first incubated with 25 μg/mL anti-FH (R&D Systems #MAB4779, Minneapolis, MN) for 90 minutes, followed by a donkey anti-mouse IgG Alexa Fluor 488 fab fragment antibody (Jackson ImmunoResearch #715-547-003, West Grove, PA) for 45 minutes. .. Sections were next incubated with 0.15 μg/mL anti-C5b-9 (Agilent #M077701-5, Santa Clara, CA) and EBL or MAL-II for 90 minutes, followed by 10 μg/mL streptavidin DyLight 549 (Vector Laboratories #SA-5549-1, Newark, CA), donkey anti-mouse IgG Alexa Fluor 647 (Invitrogen #A-31571, Waltham, MA), and 0.2 μg/mL DAPI for 45 minutes.

    Article Title: Peroxisome Proliferator-Activated Receptor Gamma (PPARγ)-targeted Gel/Mg/Lip@Gigantol nanoplatform attenuates skin barrier disruption-associated aging in mice via NLRP3 suppression.
    Article Snippet: Skin aging serves as a critical indicator of systemic health decline.. Despite Peroxisome Proliferator-Activated Receptor Gamma (PPARγ) being a key therapeutic target, mechanistic understanding remains incomplete and potent, safe activators are lacking, hindering clinical progress.. This study proposes the “Barrier-Skin-Systemic Aging Axis,” demonstrating that epidermal barrier disruption accelerates aging via PPARγ suppression.

    Article Title: Identification of an Intracellular Role for Complement Factor D: Lipid Droplet Biogenesis in Differentiating Adipocytes.
    Article Snippet: Complement factor D (CFD, also known as adipsin) is a secreted serine protease classically known for activating the alternative complement pathway and regulating systemic metabolism.. Although CFD is highly expressed in adipocytes, its roles in adipogenesis remain to be elucidated.. Here, we show that intracellularly localized CFD promoted lipid droplet (LD) formation in its catalytic activityindependent manner.

    Concentration Assay:

    Article Title: Factor H-related 1 and heparan sulfate architecture contribute to complement dysregulation in C3 glomerulopathy
    Article Snippet: .. In brief, 96-well flat bottom plates (Corning Incorporated, Corning, NY) were coated overnight with a monoclonal FHR-5 antibody (MAB3845 lot #ZFL0419071, R&D Systems, Inc., Minneapolis, MN) diluted in sodium bicarbonate/carbonate coating buffer (pH 9.6) at a final concentration of 5μg/ml. .. Plates were washed (PBST 0.05%) and blocked for 1h at room temperature (RT) with ELISA Ultra Block Buffer (Bio-Rad, Minneapolis, MN), followed by a 1h incubation with patient serum diluted 1:600 in PBST.



    Similar Products

    94
    Bio-Techne corporation mouse complement factor d/adipsin antibody
    Mouse Complement Factor D/Adipsin Antibody, supplied by Bio-Techne corporation, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/complement+factor+antibodies/Mouse+Complement+Factor+D%2FAdipsin+Antibody/custom%40af5430%4010%2E1016%2Fj%2Eisci%2E2026%2E116359
    Average 94 stars, based on 1 article reviews
    mouse complement factor d/adipsin antibody - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Hycult Biotech hm2258 rrid ab 10679352 hycult biotech
    Hm2258 Rrid Ab 10679352 Hycult Biotech, supplied by Hycult Biotech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/complement+factor+antibodies/Complement+factor+D%2C+Human%2C+mAb+D10%2F4/pmc13342188-74-72-74
    Average 94 stars, based on 1 article reviews
    hm2258 rrid ab 10679352 hycult biotech - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    93
    R&D Systems mouse cfd
    <t>Adipocyte</t> <t>ESRRA</t> positively regulates <t>Cfd</t> transcriptional expression responding to bone marrow adipocytes expansion. a Venn diagram of overlapping differentially expressed genes from RNA-seq of HFHC-fed gWAT and BMAds lineage cells in Esrra fl/fl and Esrra AKO mice ( GSE248799 ), identifying six downregulated genes encoding secreted factors. b Heatmap of selected genes. c Cf d mRNA in HFHC-fed gWAT ( n = 6) and fully differentiated mBMAds ( n = 5). d Schematic of ERRE binding sites on the mouse Cfd promoter, with ChIP fragments indicated as region 1 and 2 (R1, R2). e Luciferase activity of Cfd promoter in 3T3‑L1 cells transfected with Esrra or Ppargc1a expression plasmids ( n = 5). f Effects of compound 29 (C29) or andrographolide (AP) on ESRRA/PPARGC1A- driven Cfd promoter activity ( n = 5). g Luciferase activities of the R2-deleted (ΔR2-luc), S2-mutated (MutS2-luc) and wild-type (WT-luc) Cfd promoter ( n = 5). h ChIP assays with ESRRA antibody or IgG control in BMSCs after 4 days of adipogenic induction, with cells infected with ESRRA- or GFP-expressing adenovirus ( n = 4). i Enrichment of ESRRA at Cfd promoter in BMSCs undergoing adipogenic induction from Esrra fl/fl and Esrra AKO mice ( n = 4). j , k Immunoblots of serum CFD from HFHC-fed ( j ) and aged ( k ) groups versus control diet (CD). Ponceau S as loading control (L.C). l Serum CFD levels ( n = 6). m , n Immunoblots of CFD and Leptin in gWAT from Esrra fl/fl and Esrra AKO mice as in ( j , k ). o CFD concentrations from culture medium of gWAT explants as in ( j , k ) ( n = 5). p , q Immunoblots of bone marrow CFD as in ( j , k ). r Protein levels of ESRRA, CFD and Leptin in BMSCs and mBMAds with treatment of dexamethasone (DEX) with or without rosiglitazone (Rosi). Data are shown as mean ± SD. Statistical analysis is performed using two-sided unpaired Student’s t -test ( c ), two-way ANOVA with post-hoc Turkey’s multiple comparisons test ( l , o )
    Mouse Cfd, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/complement+factor+antibodies/Mouse+Complement+Factor+D%2FAdipsin+Antibody/pmc13128952-365-19-22
    Average 93 stars, based on 1 article reviews
    mouse cfd - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    94
    R&D Systems factor d adhipsin
    <t>Adipocyte</t> <t>ESRRA</t> positively regulates <t>Cfd</t> transcriptional expression responding to bone marrow adipocytes expansion. a Venn diagram of overlapping differentially expressed genes from RNA-seq of HFHC-fed gWAT and BMAds lineage cells in Esrra fl/fl and Esrra AKO mice ( GSE248799 ), identifying six downregulated genes encoding secreted factors. b Heatmap of selected genes. c Cf d mRNA in HFHC-fed gWAT ( n = 6) and fully differentiated mBMAds ( n = 5). d Schematic of ERRE binding sites on the mouse Cfd promoter, with ChIP fragments indicated as region 1 and 2 (R1, R2). e Luciferase activity of Cfd promoter in 3T3‑L1 cells transfected with Esrra or Ppargc1a expression plasmids ( n = 5). f Effects of compound 29 (C29) or andrographolide (AP) on ESRRA/PPARGC1A- driven Cfd promoter activity ( n = 5). g Luciferase activities of the R2-deleted (ΔR2-luc), S2-mutated (MutS2-luc) and wild-type (WT-luc) Cfd promoter ( n = 5). h ChIP assays with ESRRA antibody or IgG control in BMSCs after 4 days of adipogenic induction, with cells infected with ESRRA- or GFP-expressing adenovirus ( n = 4). i Enrichment of ESRRA at Cfd promoter in BMSCs undergoing adipogenic induction from Esrra fl/fl and Esrra AKO mice ( n = 4). j , k Immunoblots of serum CFD from HFHC-fed ( j ) and aged ( k ) groups versus control diet (CD). Ponceau S as loading control (L.C). l Serum CFD levels ( n = 6). m , n Immunoblots of CFD and Leptin in gWAT from Esrra fl/fl and Esrra AKO mice as in ( j , k ). o CFD concentrations from culture medium of gWAT explants as in ( j , k ) ( n = 5). p , q Immunoblots of bone marrow CFD as in ( j , k ). r Protein levels of ESRRA, CFD and Leptin in BMSCs and mBMAds with treatment of dexamethasone (DEX) with or without rosiglitazone (Rosi). Data are shown as mean ± SD. Statistical analysis is performed using two-sided unpaired Student’s t -test ( c ), two-way ANOVA with post-hoc Turkey’s multiple comparisons test ( l , o )
    Factor D Adhipsin, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/complement+factor+antibodies/Mouse+Complement+Factor+D%2FAdipsin+Antibody/pm41974968-294-7-8
    Average 94 stars, based on 1 article reviews
    factor d adhipsin - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    Proteintech cfb
    <t>Adipocyte</t> <t>ESRRA</t> positively regulates <t>Cfd</t> transcriptional expression responding to bone marrow adipocytes expansion. a Venn diagram of overlapping differentially expressed genes from RNA-seq of HFHC-fed gWAT and BMAds lineage cells in Esrra fl/fl and Esrra AKO mice ( GSE248799 ), identifying six downregulated genes encoding secreted factors. b Heatmap of selected genes. c Cf d mRNA in HFHC-fed gWAT ( n = 6) and fully differentiated mBMAds ( n = 5). d Schematic of ERRE binding sites on the mouse Cfd promoter, with ChIP fragments indicated as region 1 and 2 (R1, R2). e Luciferase activity of Cfd promoter in 3T3‑L1 cells transfected with Esrra or Ppargc1a expression plasmids ( n = 5). f Effects of compound 29 (C29) or andrographolide (AP) on ESRRA/PPARGC1A- driven Cfd promoter activity ( n = 5). g Luciferase activities of the R2-deleted (ΔR2-luc), S2-mutated (MutS2-luc) and wild-type (WT-luc) Cfd promoter ( n = 5). h ChIP assays with ESRRA antibody or IgG control in BMSCs after 4 days of adipogenic induction, with cells infected with ESRRA- or GFP-expressing adenovirus ( n = 4). i Enrichment of ESRRA at Cfd promoter in BMSCs undergoing adipogenic induction from Esrra fl/fl and Esrra AKO mice ( n = 4). j , k Immunoblots of serum CFD from HFHC-fed ( j ) and aged ( k ) groups versus control diet (CD). Ponceau S as loading control (L.C). l Serum CFD levels ( n = 6). m , n Immunoblots of CFD and Leptin in gWAT from Esrra fl/fl and Esrra AKO mice as in ( j , k ). o CFD concentrations from culture medium of gWAT explants as in ( j , k ) ( n = 5). p , q Immunoblots of bone marrow CFD as in ( j , k ). r Protein levels of ESRRA, CFD and Leptin in BMSCs and mBMAds with treatment of dexamethasone (DEX) with or without rosiglitazone (Rosi). Data are shown as mean ± SD. Statistical analysis is performed using two-sided unpaired Student’s t -test ( c ), two-way ANOVA with post-hoc Turkey’s multiple comparisons test ( l , o )
    Cfb, supplied by Proteintech, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/complement+factor+antibodies/Complement+factor+B+Antibody/us12595477-1578-19-20
    Average 94 stars, based on 1 article reviews
    cfb - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    88
    Proteintech isotype controls
    <t>Adipocyte</t> <t>ESRRA</t> positively regulates <t>Cfd</t> transcriptional expression responding to bone marrow adipocytes expansion. a Venn diagram of overlapping differentially expressed genes from RNA-seq of HFHC-fed gWAT and BMAds lineage cells in Esrra fl/fl and Esrra AKO mice ( GSE248799 ), identifying six downregulated genes encoding secreted factors. b Heatmap of selected genes. c Cf d mRNA in HFHC-fed gWAT ( n = 6) and fully differentiated mBMAds ( n = 5). d Schematic of ERRE binding sites on the mouse Cfd promoter, with ChIP fragments indicated as region 1 and 2 (R1, R2). e Luciferase activity of Cfd promoter in 3T3‑L1 cells transfected with Esrra or Ppargc1a expression plasmids ( n = 5). f Effects of compound 29 (C29) or andrographolide (AP) on ESRRA/PPARGC1A- driven Cfd promoter activity ( n = 5). g Luciferase activities of the R2-deleted (ΔR2-luc), S2-mutated (MutS2-luc) and wild-type (WT-luc) Cfd promoter ( n = 5). h ChIP assays with ESRRA antibody or IgG control in BMSCs after 4 days of adipogenic induction, with cells infected with ESRRA- or GFP-expressing adenovirus ( n = 4). i Enrichment of ESRRA at Cfd promoter in BMSCs undergoing adipogenic induction from Esrra fl/fl and Esrra AKO mice ( n = 4). j , k Immunoblots of serum CFD from HFHC-fed ( j ) and aged ( k ) groups versus control diet (CD). Ponceau S as loading control (L.C). l Serum CFD levels ( n = 6). m , n Immunoblots of CFD and Leptin in gWAT from Esrra fl/fl and Esrra AKO mice as in ( j , k ). o CFD concentrations from culture medium of gWAT explants as in ( j , k ) ( n = 5). p , q Immunoblots of bone marrow CFD as in ( j , k ). r Protein levels of ESRRA, CFD and Leptin in BMSCs and mBMAds with treatment of dexamethasone (DEX) with or without rosiglitazone (Rosi). Data are shown as mean ± SD. Statistical analysis is performed using two-sided unpaired Student’s t -test ( c ), two-way ANOVA with post-hoc Turkey’s multiple comparisons test ( l , o )
    Isotype Controls, supplied by Proteintech, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/complement+factor+antibodies/Complement+factor+H+Antibody/pm41781748-285-24-20
    Average 88 stars, based on 1 article reviews
    isotype controls - by Bioz Stars, 2026-11
    88/100 stars
      Buy from Supplier

    88
    Proteintech anti fh rabbit polyclonal
    <t>Adipocyte</t> <t>ESRRA</t> positively regulates <t>Cfd</t> transcriptional expression responding to bone marrow adipocytes expansion. a Venn diagram of overlapping differentially expressed genes from RNA-seq of HFHC-fed gWAT and BMAds lineage cells in Esrra fl/fl and Esrra AKO mice ( GSE248799 ), identifying six downregulated genes encoding secreted factors. b Heatmap of selected genes. c Cf d mRNA in HFHC-fed gWAT ( n = 6) and fully differentiated mBMAds ( n = 5). d Schematic of ERRE binding sites on the mouse Cfd promoter, with ChIP fragments indicated as region 1 and 2 (R1, R2). e Luciferase activity of Cfd promoter in 3T3‑L1 cells transfected with Esrra or Ppargc1a expression plasmids ( n = 5). f Effects of compound 29 (C29) or andrographolide (AP) on ESRRA/PPARGC1A- driven Cfd promoter activity ( n = 5). g Luciferase activities of the R2-deleted (ΔR2-luc), S2-mutated (MutS2-luc) and wild-type (WT-luc) Cfd promoter ( n = 5). h ChIP assays with ESRRA antibody or IgG control in BMSCs after 4 days of adipogenic induction, with cells infected with ESRRA- or GFP-expressing adenovirus ( n = 4). i Enrichment of ESRRA at Cfd promoter in BMSCs undergoing adipogenic induction from Esrra fl/fl and Esrra AKO mice ( n = 4). j , k Immunoblots of serum CFD from HFHC-fed ( j ) and aged ( k ) groups versus control diet (CD). Ponceau S as loading control (L.C). l Serum CFD levels ( n = 6). m , n Immunoblots of CFD and Leptin in gWAT from Esrra fl/fl and Esrra AKO mice as in ( j , k ). o CFD concentrations from culture medium of gWAT explants as in ( j , k ) ( n = 5). p , q Immunoblots of bone marrow CFD as in ( j , k ). r Protein levels of ESRRA, CFD and Leptin in BMSCs and mBMAds with treatment of dexamethasone (DEX) with or without rosiglitazone (Rosi). Data are shown as mean ± SD. Statistical analysis is performed using two-sided unpaired Student’s t -test ( c ), two-way ANOVA with post-hoc Turkey’s multiple comparisons test ( l , o )
    Anti Fh Rabbit Polyclonal, supplied by Proteintech, used in various techniques. Bioz Stars score: 88/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/complement+factor+antibodies/Complement+factor+H+Antibody/pm41781748-285-17-20
    Average 88 stars, based on 1 article reviews
    anti fh rabbit polyclonal - by Bioz Stars, 2026-11
    88/100 stars
      Buy from Supplier

    94
    Novus Biologicals complement factor h
    <t>Adipocyte</t> <t>ESRRA</t> positively regulates <t>Cfd</t> transcriptional expression responding to bone marrow adipocytes expansion. a Venn diagram of overlapping differentially expressed genes from RNA-seq of HFHC-fed gWAT and BMAds lineage cells in Esrra fl/fl and Esrra AKO mice ( GSE248799 ), identifying six downregulated genes encoding secreted factors. b Heatmap of selected genes. c Cf d mRNA in HFHC-fed gWAT ( n = 6) and fully differentiated mBMAds ( n = 5). d Schematic of ERRE binding sites on the mouse Cfd promoter, with ChIP fragments indicated as region 1 and 2 (R1, R2). e Luciferase activity of Cfd promoter in 3T3‑L1 cells transfected with Esrra or Ppargc1a expression plasmids ( n = 5). f Effects of compound 29 (C29) or andrographolide (AP) on ESRRA/PPARGC1A- driven Cfd promoter activity ( n = 5). g Luciferase activities of the R2-deleted (ΔR2-luc), S2-mutated (MutS2-luc) and wild-type (WT-luc) Cfd promoter ( n = 5). h ChIP assays with ESRRA antibody or IgG control in BMSCs after 4 days of adipogenic induction, with cells infected with ESRRA- or GFP-expressing adenovirus ( n = 4). i Enrichment of ESRRA at Cfd promoter in BMSCs undergoing adipogenic induction from Esrra fl/fl and Esrra AKO mice ( n = 4). j , k Immunoblots of serum CFD from HFHC-fed ( j ) and aged ( k ) groups versus control diet (CD). Ponceau S as loading control (L.C). l Serum CFD levels ( n = 6). m , n Immunoblots of CFD and Leptin in gWAT from Esrra fl/fl and Esrra AKO mice as in ( j , k ). o CFD concentrations from culture medium of gWAT explants as in ( j , k ) ( n = 5). p , q Immunoblots of bone marrow CFD as in ( j , k ). r Protein levels of ESRRA, CFD and Leptin in BMSCs and mBMAds with treatment of dexamethasone (DEX) with or without rosiglitazone (Rosi). Data are shown as mean ± SD. Statistical analysis is performed using two-sided unpaired Student’s t -test ( c ), two-way ANOVA with post-hoc Turkey’s multiple comparisons test ( l , o )
    Complement Factor H, supplied by Novus Biologicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/complement+factor+antibodies/Complement+Factor+H+Antibody+(C18%2F3)+%5BJanelia+Fluor%C2%AE+549%5D/10__1091_slash_mbc__e25___11___0547-128-18-37
    Average 94 stars, based on 1 article reviews
    complement factor h - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    Image Search Results


    Adipocyte ESRRA positively regulates Cfd transcriptional expression responding to bone marrow adipocytes expansion. a Venn diagram of overlapping differentially expressed genes from RNA-seq of HFHC-fed gWAT and BMAds lineage cells in Esrra fl/fl and Esrra AKO mice ( GSE248799 ), identifying six downregulated genes encoding secreted factors. b Heatmap of selected genes. c Cf d mRNA in HFHC-fed gWAT ( n = 6) and fully differentiated mBMAds ( n = 5). d Schematic of ERRE binding sites on the mouse Cfd promoter, with ChIP fragments indicated as region 1 and 2 (R1, R2). e Luciferase activity of Cfd promoter in 3T3‑L1 cells transfected with Esrra or Ppargc1a expression plasmids ( n = 5). f Effects of compound 29 (C29) or andrographolide (AP) on ESRRA/PPARGC1A- driven Cfd promoter activity ( n = 5). g Luciferase activities of the R2-deleted (ΔR2-luc), S2-mutated (MutS2-luc) and wild-type (WT-luc) Cfd promoter ( n = 5). h ChIP assays with ESRRA antibody or IgG control in BMSCs after 4 days of adipogenic induction, with cells infected with ESRRA- or GFP-expressing adenovirus ( n = 4). i Enrichment of ESRRA at Cfd promoter in BMSCs undergoing adipogenic induction from Esrra fl/fl and Esrra AKO mice ( n = 4). j , k Immunoblots of serum CFD from HFHC-fed ( j ) and aged ( k ) groups versus control diet (CD). Ponceau S as loading control (L.C). l Serum CFD levels ( n = 6). m , n Immunoblots of CFD and Leptin in gWAT from Esrra fl/fl and Esrra AKO mice as in ( j , k ). o CFD concentrations from culture medium of gWAT explants as in ( j , k ) ( n = 5). p , q Immunoblots of bone marrow CFD as in ( j , k ). r Protein levels of ESRRA, CFD and Leptin in BMSCs and mBMAds with treatment of dexamethasone (DEX) with or without rosiglitazone (Rosi). Data are shown as mean ± SD. Statistical analysis is performed using two-sided unpaired Student’s t -test ( c ), two-way ANOVA with post-hoc Turkey’s multiple comparisons test ( l , o )

    Journal: Bone Research

    Article Title: Targeting adipocyte ESRRA alleviates osteoarthritis via interrupting inter-organelle crosstalk of complement C3-CFD-MAC cascade

    doi: 10.1038/s41413-026-00527-3

    Figure Lengend Snippet: Adipocyte ESRRA positively regulates Cfd transcriptional expression responding to bone marrow adipocytes expansion. a Venn diagram of overlapping differentially expressed genes from RNA-seq of HFHC-fed gWAT and BMAds lineage cells in Esrra fl/fl and Esrra AKO mice ( GSE248799 ), identifying six downregulated genes encoding secreted factors. b Heatmap of selected genes. c Cf d mRNA in HFHC-fed gWAT ( n = 6) and fully differentiated mBMAds ( n = 5). d Schematic of ERRE binding sites on the mouse Cfd promoter, with ChIP fragments indicated as region 1 and 2 (R1, R2). e Luciferase activity of Cfd promoter in 3T3‑L1 cells transfected with Esrra or Ppargc1a expression plasmids ( n = 5). f Effects of compound 29 (C29) or andrographolide (AP) on ESRRA/PPARGC1A- driven Cfd promoter activity ( n = 5). g Luciferase activities of the R2-deleted (ΔR2-luc), S2-mutated (MutS2-luc) and wild-type (WT-luc) Cfd promoter ( n = 5). h ChIP assays with ESRRA antibody or IgG control in BMSCs after 4 days of adipogenic induction, with cells infected with ESRRA- or GFP-expressing adenovirus ( n = 4). i Enrichment of ESRRA at Cfd promoter in BMSCs undergoing adipogenic induction from Esrra fl/fl and Esrra AKO mice ( n = 4). j , k Immunoblots of serum CFD from HFHC-fed ( j ) and aged ( k ) groups versus control diet (CD). Ponceau S as loading control (L.C). l Serum CFD levels ( n = 6). m , n Immunoblots of CFD and Leptin in gWAT from Esrra fl/fl and Esrra AKO mice as in ( j , k ). o CFD concentrations from culture medium of gWAT explants as in ( j , k ) ( n = 5). p , q Immunoblots of bone marrow CFD as in ( j , k ). r Protein levels of ESRRA, CFD and Leptin in BMSCs and mBMAds with treatment of dexamethasone (DEX) with or without rosiglitazone (Rosi). Data are shown as mean ± SD. Statistical analysis is performed using two-sided unpaired Student’s t -test ( c ), two-way ANOVA with post-hoc Turkey’s multiple comparisons test ( l , o )

    Article Snippet: The antibodies used for immunoblot analysis included ESRRA (1:1 000, Cell Signaling Technology #13826), Tubulin (1:5 000, BPI #AbM59005-37B-PU), mouse CFD (1:800, R&D Systems #AF5430), human CFD (ABclonal #A23006), C3 (1:5 000, ABclonal #A13283), GAPDH (1:5 000, Proteintech #60004-1-Ig), COL2A1 (1:800, Proteintech #28459-1-AP), MMP13 (1:1 000, Proteintech #18165-1-AP), P21 (1:1 000, Proteintech #28248-1-AP), pERK1/2 (1:2 000, Abmart #T40072S), ERK1/2 (1:2 000, Abmart #T40071S), and Leptin (1:500, Abcam #ab16227).

    Techniques: Expressing, RNA Sequencing, Binding Assay, Luciferase, Activity Assay, Transfection, Control, Infection, Western Blot

    Reduced CFD from Esrra -ablated BMAds interrupts C3-CFD-MAC cascade-mediated mitochondrial dysfunction, senescence and catabolism in chondrocytes. a , b Representative images ( a ) and quantification ( b ) of MAC and pERK1/2 positive staining in cartilage regions of HFHC-fed or 25-month-old Esrra fl/fl and Esrra AKO mice. Scale bar, 100 μm. n = 6 mice. c Diagram depicting primary wild-type chondrocytes treated with the indicated conditioned medium (CM) collected from mBMAds, with or without supplementation of 1 μg/mL mouse recombinant C3 (mC3). d Soluble CFD concentrations from BMAds CM prepared as in ( c ) ( n = 6). e mRNA levels of degradative enzymes Mmp13 , Mmp3 , Mmp9 , Adamts4 , Adamts5 and senescent/proinflammatory markers P16 , P53 , P21 , IL6 in co-cultured primary chondrocytes as in ( c ) ( n = 5). f Protein levels of pERK1/2, ERK1/2, P21, MMP13 and COL2A1 in co-cultured primary chondrocytes as in ( c ). g , h Immunofluorescence staining of MAC, pERK1/2, MitoTracker Red, MitoSOX Red, γH2AX, P21 and Ki67, as well as SA-β-gal staining in co-cultured primary chondrocytes ( g ). Quantitative analysis results are shown in ( h ) ( n = 4). DAPI or Hoechst was used for nuclear counterstaining. Scale bar, 10 μm. i Oxygen Consumption Rate (OCR) were measured in co-cultured primary chondrocytes as in ( c ). Bar chart showing the results of mitochondrial basal and maximal respiratory capacity changes ( n = 9). Data are shown as mean ± SD. Statistical analysis is performed using two-sided unpaired Student’s t -test ( b , d ), two-way ANOVA with post-hoc Turkey’s multiple comparisons test ( e , h , i )

    Journal: Bone Research

    Article Title: Targeting adipocyte ESRRA alleviates osteoarthritis via interrupting inter-organelle crosstalk of complement C3-CFD-MAC cascade

    doi: 10.1038/s41413-026-00527-3

    Figure Lengend Snippet: Reduced CFD from Esrra -ablated BMAds interrupts C3-CFD-MAC cascade-mediated mitochondrial dysfunction, senescence and catabolism in chondrocytes. a , b Representative images ( a ) and quantification ( b ) of MAC and pERK1/2 positive staining in cartilage regions of HFHC-fed or 25-month-old Esrra fl/fl and Esrra AKO mice. Scale bar, 100 μm. n = 6 mice. c Diagram depicting primary wild-type chondrocytes treated with the indicated conditioned medium (CM) collected from mBMAds, with or without supplementation of 1 μg/mL mouse recombinant C3 (mC3). d Soluble CFD concentrations from BMAds CM prepared as in ( c ) ( n = 6). e mRNA levels of degradative enzymes Mmp13 , Mmp3 , Mmp9 , Adamts4 , Adamts5 and senescent/proinflammatory markers P16 , P53 , P21 , IL6 in co-cultured primary chondrocytes as in ( c ) ( n = 5). f Protein levels of pERK1/2, ERK1/2, P21, MMP13 and COL2A1 in co-cultured primary chondrocytes as in ( c ). g , h Immunofluorescence staining of MAC, pERK1/2, MitoTracker Red, MitoSOX Red, γH2AX, P21 and Ki67, as well as SA-β-gal staining in co-cultured primary chondrocytes ( g ). Quantitative analysis results are shown in ( h ) ( n = 4). DAPI or Hoechst was used for nuclear counterstaining. Scale bar, 10 μm. i Oxygen Consumption Rate (OCR) were measured in co-cultured primary chondrocytes as in ( c ). Bar chart showing the results of mitochondrial basal and maximal respiratory capacity changes ( n = 9). Data are shown as mean ± SD. Statistical analysis is performed using two-sided unpaired Student’s t -test ( b , d ), two-way ANOVA with post-hoc Turkey’s multiple comparisons test ( e , h , i )

    Article Snippet: The antibodies used for immunoblot analysis included ESRRA (1:1 000, Cell Signaling Technology #13826), Tubulin (1:5 000, BPI #AbM59005-37B-PU), mouse CFD (1:800, R&D Systems #AF5430), human CFD (ABclonal #A23006), C3 (1:5 000, ABclonal #A13283), GAPDH (1:5 000, Proteintech #60004-1-Ig), COL2A1 (1:800, Proteintech #28459-1-AP), MMP13 (1:1 000, Proteintech #18165-1-AP), P21 (1:1 000, Proteintech #28248-1-AP), pERK1/2 (1:2 000, Abmart #T40072S), ERK1/2 (1:2 000, Abmart #T40071S), and Leptin (1:500, Abcam #ab16227).

    Techniques: Staining, Recombinant, Cell Culture, Immunofluorescence

    Inhibition of adipocyte ESRRA/CFD signaling rescues chondrocyte from damage caused by excessive hepatocytes-derived C3 under metabolic stress conditions. a Boxplots depicting C3 gene expression levels in MASLD/MASH patients compared to healthy controls from European ( GSE135251 ) and American ( GSE24807 ) cohorts. Data are represented as box and whiskers with bars representing maximum and minimum values and with median highlighted as a line. b Immunoblot analysis of C3 expression in livers from female mice at various time points following OVX (left) and male mice across different ages (right). c Representative liver images of the livers from HFHC-fed or 25-month-old Esrra fl/fl and Esrra AKO mice as well as corresponding controls. d Protein levels of C3 in the livers as in ( c ). e ELISA analysis of serum C3 concentrations. n = 6 mice per group. f The expression and secretion of C3 protein in primary hepatocytes following treatment with 40 μmol/L cholesterol (Chol) or a mixture of 250 μmol/L oleic acid (OA)/125 μmol/L palmitic acid (PA) for 24 hours (n = 4). g Diagram illustrating the co-culture system involving mBMAds CM, mouse primary hepatocytes and chondrocytes. h Western blot analysis of pERK1/2, ERK1/2, P21, MMP13 and COL2A1 in co-cultured primary chondrocytes as in ( g ). i , j Representative images ( i ) and quantitative analysis ( j ) of MAC, pERK1/2, MitoTracker Red, MitoSOX Red, γH2AX, P21, Ki67 and SA-β-gal staining in chondrocytes as in ( g ) ( n = 4). DAPI or Hoechst was used for counterstaining of nuclei. Scale bar, 10 μm. Data are shown as mean ± SD. Statistical analysis is performed using two-sided unpaired Student’s t -test (right panel of a ), two-way ANOVA with post-hoc Turkey’s multiple comparisons test ( e , j ), one-way ANOVA followed by Bonferroni’s post hoc tests (left panel of a , f )

    Journal: Bone Research

    Article Title: Targeting adipocyte ESRRA alleviates osteoarthritis via interrupting inter-organelle crosstalk of complement C3-CFD-MAC cascade

    doi: 10.1038/s41413-026-00527-3

    Figure Lengend Snippet: Inhibition of adipocyte ESRRA/CFD signaling rescues chondrocyte from damage caused by excessive hepatocytes-derived C3 under metabolic stress conditions. a Boxplots depicting C3 gene expression levels in MASLD/MASH patients compared to healthy controls from European ( GSE135251 ) and American ( GSE24807 ) cohorts. Data are represented as box and whiskers with bars representing maximum and minimum values and with median highlighted as a line. b Immunoblot analysis of C3 expression in livers from female mice at various time points following OVX (left) and male mice across different ages (right). c Representative liver images of the livers from HFHC-fed or 25-month-old Esrra fl/fl and Esrra AKO mice as well as corresponding controls. d Protein levels of C3 in the livers as in ( c ). e ELISA analysis of serum C3 concentrations. n = 6 mice per group. f The expression and secretion of C3 protein in primary hepatocytes following treatment with 40 μmol/L cholesterol (Chol) or a mixture of 250 μmol/L oleic acid (OA)/125 μmol/L palmitic acid (PA) for 24 hours (n = 4). g Diagram illustrating the co-culture system involving mBMAds CM, mouse primary hepatocytes and chondrocytes. h Western blot analysis of pERK1/2, ERK1/2, P21, MMP13 and COL2A1 in co-cultured primary chondrocytes as in ( g ). i , j Representative images ( i ) and quantitative analysis ( j ) of MAC, pERK1/2, MitoTracker Red, MitoSOX Red, γH2AX, P21, Ki67 and SA-β-gal staining in chondrocytes as in ( g ) ( n = 4). DAPI or Hoechst was used for counterstaining of nuclei. Scale bar, 10 μm. Data are shown as mean ± SD. Statistical analysis is performed using two-sided unpaired Student’s t -test (right panel of a ), two-way ANOVA with post-hoc Turkey’s multiple comparisons test ( e , j ), one-way ANOVA followed by Bonferroni’s post hoc tests (left panel of a , f )

    Article Snippet: The antibodies used for immunoblot analysis included ESRRA (1:1 000, Cell Signaling Technology #13826), Tubulin (1:5 000, BPI #AbM59005-37B-PU), mouse CFD (1:800, R&D Systems #AF5430), human CFD (ABclonal #A23006), C3 (1:5 000, ABclonal #A13283), GAPDH (1:5 000, Proteintech #60004-1-Ig), COL2A1 (1:800, Proteintech #28459-1-AP), MMP13 (1:1 000, Proteintech #18165-1-AP), P21 (1:1 000, Proteintech #28248-1-AP), pERK1/2 (1:2 000, Abmart #T40072S), ERK1/2 (1:2 000, Abmart #T40071S), and Leptin (1:500, Abcam #ab16227).

    Techniques: Inhibition, Derivative Assay, Gene Expression, Western Blot, Expressing, Enzyme-linked Immunosorbent Assay, Co-Culture Assay, Cell Culture, Staining

    Suppressing CFD by Danicopan or andrographolide confers protection against cellular senescence and catabolism in human C28/I2 chondrocytes. a Scatter plot showing plasma CFD levels across the lifespan were analyzed using a public proteome dataset (see Method for details). RFU, relative fluorescent unit. b Illustration of the co-culture system involving C28/I2 chondrocytes and conditioned medium (CM) obtained from AP-treated human BMAds (hBMAds), with an additional treatment of 1 μg/mL human recombinant C3 (hC3) and/or 10 mmol/L Danicopan. c Western blot analysis of ESRRA, CFD and Leptin protein levels in human BMSCs-derived BMAds treated with 40 μmol/L AP or DMSO for 2 days. d Western blot analysis of pERK1/2, ERK1/2, P21, MMP13, and COL2A1 protein levels in human C28/I2 chondrocytes as in ( b ). e , f Representative images ( e ) and corresponding quantitative data ( f ) of MAC, pERK1/2, MitoTracker Red, MitoSOX Red, γH2AX, P21, Ki67 and SA-β-gal staining in human C28/I2 chondrocytes as in ( b ) ( n = 4). DAPI or Hoechst was used for nuclear counterstaining. Scale bar, 10 μm. Data are shown as mean ± SD. Statistical analysis is performed using two-way ANOVA with post-hoc Turkey’s multiple comparisons test

    Journal: Bone Research

    Article Title: Targeting adipocyte ESRRA alleviates osteoarthritis via interrupting inter-organelle crosstalk of complement C3-CFD-MAC cascade

    doi: 10.1038/s41413-026-00527-3

    Figure Lengend Snippet: Suppressing CFD by Danicopan or andrographolide confers protection against cellular senescence and catabolism in human C28/I2 chondrocytes. a Scatter plot showing plasma CFD levels across the lifespan were analyzed using a public proteome dataset (see Method for details). RFU, relative fluorescent unit. b Illustration of the co-culture system involving C28/I2 chondrocytes and conditioned medium (CM) obtained from AP-treated human BMAds (hBMAds), with an additional treatment of 1 μg/mL human recombinant C3 (hC3) and/or 10 mmol/L Danicopan. c Western blot analysis of ESRRA, CFD and Leptin protein levels in human BMSCs-derived BMAds treated with 40 μmol/L AP or DMSO for 2 days. d Western blot analysis of pERK1/2, ERK1/2, P21, MMP13, and COL2A1 protein levels in human C28/I2 chondrocytes as in ( b ). e , f Representative images ( e ) and corresponding quantitative data ( f ) of MAC, pERK1/2, MitoTracker Red, MitoSOX Red, γH2AX, P21, Ki67 and SA-β-gal staining in human C28/I2 chondrocytes as in ( b ) ( n = 4). DAPI or Hoechst was used for nuclear counterstaining. Scale bar, 10 μm. Data are shown as mean ± SD. Statistical analysis is performed using two-way ANOVA with post-hoc Turkey’s multiple comparisons test

    Article Snippet: The antibodies used for immunoblot analysis included ESRRA (1:1 000, Cell Signaling Technology #13826), Tubulin (1:5 000, BPI #AbM59005-37B-PU), mouse CFD (1:800, R&D Systems #AF5430), human CFD (ABclonal #A23006), C3 (1:5 000, ABclonal #A13283), GAPDH (1:5 000, Proteintech #60004-1-Ig), COL2A1 (1:800, Proteintech #28459-1-AP), MMP13 (1:1 000, Proteintech #18165-1-AP), P21 (1:1 000, Proteintech #28248-1-AP), pERK1/2 (1:2 000, Abmart #T40072S), ERK1/2 (1:2 000, Abmart #T40071S), and Leptin (1:500, Abcam #ab16227).

    Techniques: Clinical Proteomics, Co-Culture Assay, Recombinant, Western Blot, Derivative Assay, Staining

    Pharmacological inhibition of ESRRA by andrographolide protects aged mice against spontaneous osteoarthritis progression. a Schematic diagram of the experimental design for pharmacological treatments in mice. 22-month-old male C57BL/6 mice were administered intragastrically (i.g.) with either vehicle or AP (100 mg/kg body weight) five times per week for 3 months. Young controls were 3-month-old male mice. b Representative images of WAT depots and livers, along with WAT weight analysis. c Liver TC and TG levels. d Immunoblots of C3 in liver tissues. e Serum C3 levels. f Immunoblots of bone marrow CFD and Leptin. g Serum CFD levels. h , i Immunofluorescence of PLIN1 staining ( h ) and quantification of PLIN1 + bone marrow adipocytes area ( i ). Scale bar, 100 μm. j Representative SO&FG-stained joint sections and H&E-stained synovial tissue. Scale bar, 100 μm. k , l OARSI score ( k ) and synovitis score ( l ). m Digital microCT images of knee joints. n , Quantitative data of the volume of calcified meniscus and synovial tissue. o , p Immunofluorescence staining for MAC and pERK1/2 in articular cartilage ( o ) and the quantitation ( p ). Scale bar, 100 μm. q – t Immunofluorescence staining ( q , r ) and quantification ( s , t ) of p21, Ki67, MMP13 and COL2A1. Scale bar, 100 μm. u A proposed model illustrates that ESRRA-mediated adipocyte CFD and liver-derived C3 synergistically promote osteoarthritis progression in aging and metabolic disorders. ESRRA transcriptionally upregulates CFD responding to MAT expansion. Together with steatotic liver-derived C3, this triggers excessive alternative complement activation, resulting in MAC deposition on chondrocytes, therefore provoking pERK1/2 activation and mitochondrial dysfunction. Targeting ESRRA alleviates osteoarthritis by interrupting this inter-organ C3-CFD-MAC cascade. For all experiments, n = 6 mice. Data are shown as mean ± SD. Statistical analysis is performed using two-way ANOVA with post-hoc Turkey’s multiple comparisons test

    Journal: Bone Research

    Article Title: Targeting adipocyte ESRRA alleviates osteoarthritis via interrupting inter-organelle crosstalk of complement C3-CFD-MAC cascade

    doi: 10.1038/s41413-026-00527-3

    Figure Lengend Snippet: Pharmacological inhibition of ESRRA by andrographolide protects aged mice against spontaneous osteoarthritis progression. a Schematic diagram of the experimental design for pharmacological treatments in mice. 22-month-old male C57BL/6 mice were administered intragastrically (i.g.) with either vehicle or AP (100 mg/kg body weight) five times per week for 3 months. Young controls were 3-month-old male mice. b Representative images of WAT depots and livers, along with WAT weight analysis. c Liver TC and TG levels. d Immunoblots of C3 in liver tissues. e Serum C3 levels. f Immunoblots of bone marrow CFD and Leptin. g Serum CFD levels. h , i Immunofluorescence of PLIN1 staining ( h ) and quantification of PLIN1 + bone marrow adipocytes area ( i ). Scale bar, 100 μm. j Representative SO&FG-stained joint sections and H&E-stained synovial tissue. Scale bar, 100 μm. k , l OARSI score ( k ) and synovitis score ( l ). m Digital microCT images of knee joints. n , Quantitative data of the volume of calcified meniscus and synovial tissue. o , p Immunofluorescence staining for MAC and pERK1/2 in articular cartilage ( o ) and the quantitation ( p ). Scale bar, 100 μm. q – t Immunofluorescence staining ( q , r ) and quantification ( s , t ) of p21, Ki67, MMP13 and COL2A1. Scale bar, 100 μm. u A proposed model illustrates that ESRRA-mediated adipocyte CFD and liver-derived C3 synergistically promote osteoarthritis progression in aging and metabolic disorders. ESRRA transcriptionally upregulates CFD responding to MAT expansion. Together with steatotic liver-derived C3, this triggers excessive alternative complement activation, resulting in MAC deposition on chondrocytes, therefore provoking pERK1/2 activation and mitochondrial dysfunction. Targeting ESRRA alleviates osteoarthritis by interrupting this inter-organ C3-CFD-MAC cascade. For all experiments, n = 6 mice. Data are shown as mean ± SD. Statistical analysis is performed using two-way ANOVA with post-hoc Turkey’s multiple comparisons test

    Article Snippet: The antibodies used for immunoblot analysis included ESRRA (1:1 000, Cell Signaling Technology #13826), Tubulin (1:5 000, BPI #AbM59005-37B-PU), mouse CFD (1:800, R&D Systems #AF5430), human CFD (ABclonal #A23006), C3 (1:5 000, ABclonal #A13283), GAPDH (1:5 000, Proteintech #60004-1-Ig), COL2A1 (1:800, Proteintech #28459-1-AP), MMP13 (1:1 000, Proteintech #18165-1-AP), P21 (1:1 000, Proteintech #28248-1-AP), pERK1/2 (1:2 000, Abmart #T40072S), ERK1/2 (1:2 000, Abmart #T40071S), and Leptin (1:500, Abcam #ab16227).

    Techniques: Inhibition, Western Blot, Immunofluorescence, Staining, Quantitation Assay, Derivative Assay, Activation Assay